Debio 1450

Drug Profile

Debio 1450

Alternative Names: AFN 1720; AFN-1252-prodrug; Debio-1452-prodrug; Debio1450

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Affinium Pharmaceuticals
  • Developer Debiopharm Group
  • Class Anti-infectives; Small molecules
  • Mechanism of Action Enoyl-ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteomyelitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Bone and joint infections; Skin and soft tissue infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Skin and soft tissue infections
  • Phase I Bone and joint infections; Staphylococcal infections

Most Recent Events

  • 10 Jan 2017 Topline efficacy data from phase II trial in Skin and soft tissue infections released by Debiopharm Group
  • 25 Oct 2016 Debio 1450 receives Orphan Drug status for Osteomyelitis in European Union
  • 25 Oct 2016 Debiopharm completes a phase II trial in Acute bacterial skin and skin structure infections in USA (NCT02426918)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top